Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant

Leukemia and Lymphoma

Volumn 56, Issue 6, 2015, Pages 1710-1717

  Li, Juan ^a   Huang, Beihui ^a   Li, Ying ^a   Zheng, Dong ^a   Zhou, Zhenhai ^a   Liu, Junru ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Hepatitis B reactivation; Myeloma; Nucleoside analog

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; THALIDOMIDE; VIRUS DNA; ANTINEOPLASTIC AGENT; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; RETROSPECTIVE STUDY; VIRUS REACTIVATION; AUTOTRANSPLANTATION; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; MORTALITY; PHYSIOLOGY; PROGNOSIS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; VIROLOGY; VIRUS ACTIVATION;

ADULT; ANTINEOPLASTIC AGENTS; BORTEZOMIB; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; VIRUS ACTIVATION;

EID: 84928999746     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.941833     Document Type: Article

References (45)

1. Sun Z, Ming L, Zhu X, et al. Prevention and control of hepatitis B in China. J Med Virol 2002; 67: 447-450.
2. Yeo W, Chan P K, Zhong S, et al. F requency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307.
3. Hoofnagle J H. R eactivation of hepatitis B. H epatology 2 009; 4 9: S156-S165.
4. Huang B, Li J, Zhou Z, et al. High prevalence of hepatitis B virus infection in multiple myeloma. Leuk Lymphoma 2012; 53: 270-274.
5. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009; 49: 1211-1225.
6. Yeo W, Johnson P J. D iagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-220.
7. Yeo W, Zee B, Zhong S, et al. C omprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-1311.
8. Papamichalis P, Alexiou A, Boulbou M, et al. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy. Clin Res Hepatol Gastroenterol 2012; 36: 84-93.
9. Cheng AL, Hsiung CA, Su IJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37: 1320-1328.
10. Hernandez J A, Diloy R, Salat D, et al. F ulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab. Haematologica 2003; 88:ECR22.
11. Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn ' s disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-1365.
12. Lau GK, Liang R, Chiu EK, et al. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: A case controlled study. Bone Marrow Transplant 1997; 19: 795-799.
13. Kempinska A, Kwak EJ, Angel JB. Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature. Clin Infect Dis 2005; 41: 1277-1282.
14. Martin BA, Rowe JM, Kouides PA, et al. Hepatitis B reactivation following allogeneic bone marrow transplantation: case report and review of the literature. Bone Marrow Transplant 1995; 15: 145-148.
15. Yeo W, Lam KC, Zee B, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004; 15: 1661-1666.
16. Lau G K, Leung Y H, Fong D Y, et al. H igh hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002; 99: 2324-2330.
17. Hui C K, Bowden S, Jackson K, et al. C linical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy. Blood 2005; 105: 2616-2617.
18. Jang J W, Choi J Y, Bae S H, et al. T ransarterial chemolipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol 2004; 41: 427-435.
19. Zhong S, Yeo W, Schroder C, et al. E fficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 2004; 11: 55-59.
20. Nagamatsu H, Kumashiro R, Itano S, et al. Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC. Hepatol Res 2003; 26: 293-301.
21. Dai MS, Wu PF, Lu JJ, et al. Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: A longitudinal study. Support Care Cancer 2004; 12: 191-196.
22. Shibolet O, Ilan Y, Gillis S, et al. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002; 100: 391-396.
23. Persico M, De Marino F, Russo GD, et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 2002; 99: 724-725.
24. Ozguroglu M, Bilici A, Turna H, et la. Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin ' s lymphoma. Med Oncol 2004; 21: 67-72.
25. Leaw SJ, Yen CJ, Huang WT, et al. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 2004; 83: 270-275.
26. Yeo W, Chan P K, Ho W M, et al. L amivudine for the prevention of hepatitis B virus reactivation in hepatitis B s- Antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22: 927-934.
27. Yeo W, Ho WM, Hui P, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 2004; 88: 209-215.
28. Jang J W, Choi J Y, Bae S H, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006; 43: 233-240.
29. Lau GK, He ML, Fong DY, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002; 36: 702-709.
30. Mya DH, Han ST, Linn YC, et al. Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection. Ann Oncol 2012; 23: 421-426.
31. Tanaka H, Sakuma I, Hashimoto S, et al. Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy: case report. J Clin Exp Hematop 2012; 52: 67-69.
32. Huang H, Cai Q, Lin T, et al. L amivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin ' s lymphoma single institution experience. Expert Opin Pharmacother 2009; 10: 2399-2406.
33. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol Int 2008; 2: 263-283.
34. de Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003; 39(Suppl. 1): S3-S25.
35. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539.
36. Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57: 1-20.
37. European Association for the Study of the Liver. E ASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
38. Schütt P, Brandhorst D, Stellberg W, et al. I mmune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma 2006; 47: 1570-1582.
39. Ogawara H, Handa H, Yamazaki T, et al. High Th 1/Th 2 ratio in patients with multiple myeloma. Leuk Res 2005; 29: 135-140.
40. Basler M, Lauer C, Beck U, et al. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol 2009; 183: 6145-6150.
41. V ogelbacher R, Meister S, Gückel E, et al. B ortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat. Nephrol Dial Transplant 2010; 25: 3764-3773.
42. Wils EJ, van der Holt B, Broers AE, et al. Insufficient recovery of thymopoiesis predicts for opportunistic infections in allogeneic hematopoietic stem cell transplant recipients. Haematologica 2011; 96: 1846-1854.
43. Steingrimsdottir H, Gruber A, Bjorkholm M, et al. I mmune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications. Haematologica 2000; 85: 832-838.
44. Li H, Wu K, Tao K, et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus- Associ. hepatocellular carcinoma. Hepatology 2012; 56: 1342-1351.
45. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatol Intern 2012; 6: 531-561.